FDA approves over the counter sale of naloxone to reverse drug overdosesBMJ 2023; 380 doi: https://doi.org/10.1136/bmj.p749 (Published 30 March 2023) Cite this as: BMJ 2023;380:p749
- Janice Hopkins Tanne
- New York
The US Food and Drug Administration (FDA) has approved the sale of naloxone, a nasal spray known as Narcan, without a prescription as an emergency treatment to reverse drug overdoses.
Announcing the decision on 29 March, the FDA said in a statement, “Today’s action paves the way for the life saving medication to be sold directly to consumers in places like drug stores, convenience stores, grocery stores, and gas stations, as well as online.”1
In the 12 months to October 2022, more than 101 750 people died of a drug overdose in the US, primarily because of synthetic opioids such as illegal fentanyl, the FDA said. Emergent BioSolutions, Narcan’s manufacturer, said in a press release, “The decision comes at …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.